Sort   by:  
 Page size 
UnknownA CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study.
Not available
S-EPMC8229740 | biostudies-literature
UnknownA multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Not available
S-EPMC6343690 | biostudies-literature
UnknownExploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
Not available
S-EPMC9870907 | biostudies-literature
UnknownThe prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Not available
S-EPMC8253801 | biostudies-literature
UnknownA retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Not available
S-EPMC5593613 | biostudies-literature
UnknownClinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
Not available
S-EPMC5548975 | biostudies-literature
UnknownScreening and diagnostic breast MRI: how do they impact surgical treatment? Insights from the MIPA study.
Not available
S-EPMC10415233 | biostudies-literature
UnknownChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
Not available
S-EPMC8858449 | biostudies-literature
UnknownLoss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Not available
S-EPMC7731769 | biostudies-literature
UnknownContemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry.
Not available
S-EPMC12803666 | biostudies-literature
Sort   by:  
 Page size